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Abstract
Monitoring of the workforce in the nuclear industries is carried out primarily in
order to demonstrate compliance with European Union Basic Safety Standards
for the protection of the health of workers against the dangers arising from
ionizing radiation. There is however no compilation of information on internal
dose monitoring programmes currently in use in the EU countries. Surveys
were therefore  carried out in which organisations were asked to provide
information on the design of their internal dose monitoring programmes and on
the costs of these programmes. Information was requested from both EU
countries and Associated States. Databases for storage and reporting of all
information gained were constructed, and results from the surveys compiled.
This work was carried out within the EC 5th Framework Programme project
OMINEX (Optimisation of Monitoring for Internal Exposure), which aims to
provide advice and guidance on designing and implementing internal dose
monitoring programmes in the workplace in such a way that best use is made of
available resources, while minimising costs. This paper gives the results of the
survey of the design of internal dose monitoring programmes. A major
conclusion is that, particularly for the actinides, a wide range of approaches to
monitoring are in use. There is no consensus on primary monitoring methods.
All organisations monitor workers to assess individual doses for entry onto a
legal dose record. Cumulative distributions show that most organisations aim
to assess doses down to 0.1 – 0.5 mSv.
T Rahola, G Etherington, P Bérard , B Le Guen, C Hurtgen , M Muikku, S Pusa.
Survey of international dose monitoring programmes for radiation workers. WP
1 in the project OMINEX- (Optimisation of Monitoring for Internal Exposure).
STUK-A203. Helsinki 2004. 49 + 35 s.  Englanninkielinen.
Avainsanat  monitorointi, säteilytyöntekijät, sisäinen annos, fissio- ja
aktivointituotteet, aktiniidit
Tiivistelmä
Säteilytyöntekijöitä monitoroidaan ensisijaisesti, jotta voitaisiin varmistaa että
Euroopan unionin turvallisuusvaatimukset työntekijöiden säteilysuojelusta
täyttyvät. Mitään yhteenvetoa EU maissa käytettävistä monitorointiohjelmista
ei ole. Siksi tehtiin kyselyjä käytössä olevista ohjelmista ja niiden kustannuk-
sista. Työ tehtiin Euroopan komission viidenteen puiteohjelmaan sisältyvässä
projektissa OMINEX (Optimisation of Monitoring for Internal Exposure) jonka
tarkoituksena on antaa neuvoja ja ohjausta sisäisten annosten
monitorointiohjelmien luomisessa ja implementoimisessa työpaikoilla siten,
että olemassa olevat resurssit käytetään mahdollisimman tehokkaasti samalla
kuluja minimoiden. Raportissa esitellään kyselytutkimuksen tulokset. Vasta-
ukset on tallennettu tietokantoihin. Selvitettiin minkälaisia sisäisten annosten
arviointiin tähtääviä monitorointiohjelmia on käytössä. Päällimmäinen johto-
päätös on, että erityisesti aktiniidien kohdalla tavat monitoroida vaihtelevat
paljon.  Mitään yhtenäistä näkemystä siitä miten annoksia pitäisi arvioida ei
löytynyt. Kaikki organisaatiot ilmoittavat monitoroivansa työntekijöitä henki-
lökohtaisten annosten arvioimiseksi ja annosten rekisteröimiseksi.
Kumulatiiviset jakautumat osoittavat , että useimmat organisaatiot pyrkivät
arvioimaan niinkin pieniä annoksia kuin 0,1-0,5 mSv.
5STUK-A203
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1 Introduction
OMINEX (Optimisation of Monitoring for Internal Exposure) is a 3-year
project funded by the European Commission within its 5th Framework
Programme (1). The aim of OMINEX is to provide advice and guidance on
designing and implementing internal dose monitoring programmes in the
workplace in such a way that best use is made of available resources, while
minimising costs. The project is being carried out by a consortium of research/
advisory organisations [NRPB (UK), IPSN (France), STUK (Finland), SCK-CEN
(Belgium), CEA (France)] and nuclear industry organisations [EdF (France),
TVONS (Finland)]. The UK nuclear industry is also providing a significant
input.
Monitoring of the workforce in the nuclear industries is carried out
primarily in order to demonstrate compliance with European Union Basic
Safety Standards for the protection of the health of workers against the dangers
arising from ionizing radiation. There is however no compilation of information
on internal dose monitoring programmes currently in use in the EU countries.
Such information can be collected either by requesting information directly
from organisations about their monitoring regimes or by searching the open
literature. Up-to-date information can only be obtained by carrying out a
survey, however, and so this was the chosen method. The drawback is that
participation in such a survey is of course voluntary, and so it is not always easy
to obtain responses. The statistical information that can be found in the open
literature on methods used for monitoring of internal contamination of workers
is very scarce. Trends in worldwide average annual doses to workers were
published by UNSCEAR in 1988 as also the trends in worldwide average annual
number of monitored workers. No separate trends for internal surveillance was
published.  Figures 1 and 2 illustrate the above mentioned trends. It can be
noted that the average effective doses are decreasing while the numbers of
monitored workers  are increasing from the period 1975-1979 to 1990-1994.
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Fig 1. Trends in worldwide average annual number of monitored workers (UNSCEAR)
Fig 2. Trends in worldwide average annual doses to workers (UNSCEAR)
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2 Methods
Two questionnaires were designed; the first was a 1-page “pre-questionnaire”,
while the second was a comprehensive questionnaire on the design of internal
dose monitoring programmes. Radiation safety experts in industrial
organisations were consulted regarding the content of both questionnaires.
Both questionnaires are in the form of formatted MS Word™ documents. The
monitoring programme questionnaire covers direct (in vivo) and indirect
(bioassay and air sampling) monitoring for internal exposure to fission and
activation products (FAP), and to compounds of uranium, thorium, plutonium,
americium and other actinides and to mixed oxide (MOX) material. Separate
sections cover routine and special monitoring. Six types of operations were
identified. The complete questionnaire is quite long (55 A4 pages), and so to
encourage Dosimetry Services to respond, only those parts of the questionnaire
that are relevant to the work of a particular organisation was sent out.
Identifying appropriate people to whom the questionnaires should be sent was
straightforward for countries represented in the consortium. For other
countries, however, it was often more difficult and especially more time
consuming than expected. Suitable contacts were identified in the relevant
organisations in each country; in general, these were radiation protection
professionals with direct responsibility for internal dose monitoring in the
organisation.
Before sending out the complete questionnaire, the one-page “pre-
questionnaire” was distributed in order to establish the radionuclides
monitored and monitoring methods used. This information was then used to
select those sections of the main questionnaire to be sent to the organisation.
Some persons sending in responses did not answer each question
unambiguously, which made the analysis difficult in some cases.
Databases were constructed for storage and reporting of all of the
information gathered. Responses to the monitoring programme questionnaire
were collected in a a Microsoft Access 97™ data base. Data was recorded in 39
tables arranged according to the subtitles in the questionnaire starting with
general aspects such as type of operation, number of workers, monitoring
practice and purposes of monitoring followed by data on methods of monitoring
of fission and activation products and actinides. Data on chemical forms,
calibration methods, minimum detectable amounts (MDA), monitoring
frequencies and investigation levels were included. Lastly, information on dose
assessment methods and dose statistics was recorded. All results from the
survey will be kept anonymous.
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The monitoring programme questionnaire was sent to every country
within the European Union (EU) where internal dose monitoring is carried
out, and also to the “Associated States” of the EU. In addition, the
questionnaire was sent to organisations in countries with large nuclear
power programmes (eg the USA) who might be able to provide useful
information.
10
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3 Results
General
Responses to the monitoring programme “pre-questionnaire” were received
from 58 organisations, from EU countries (29), from Associated States (10) and
from countries outside of the EU/Associated States (19). Table 1 gives the
information on number of types of operations and types of monitoring and table
2 types of operation and radionuclides monitored at each type of organisation.
About half of the organisations represented nuclear power plants and one third
research organisations. Most used is direct in vivo monitoring closely followed
by bioassay monitoring mostly in research institutes. At nuclear power plants
fission and activation products (FAP) are most frequently monitored. In
research institutes the need to monitor uranium, plutonium, thorium and
americium is clearly seen.
Responses to the monitoring programme questionnaire were received
from 29 organisations (50 per cent of those answering the “pre-questionnaire”),
22 from EU countries and 7 from Associated States but none from countries
outside of the EU/Associated States. Four EU countries answered that they
have routine monitoring only for external dose assessment and would use
foreign expertise for internal monitoring and dose assessment if needed. Table
3a gives general information on the number of organisations responding to the
survey (WP 1 questionnaire) and the number of workers in the different
organisations in EU States, Associated States and other countries. We were not
able to get any response to the questionnaire from seven countries that during
personal contact explained that they had no established organisation for
internal dose monitoring and dosimetry. service. The lack of response may also
have been because we did not approach the right person.
Although this survey is not comprehensive across the EU it does present
a representative view. The survey provides a representative coverage of the 6
types of operation identified. Size of organisation ranges from 155,000 workers,
down to 70 workers; median slightly less than 1000. Some organisations
presented a combined response from a large number of sites. Tables 4a and 4b
show the distribution of workers in Categories A and B (categorisation of
workers is described in EC Directive 96/29/EURATOM (European Commission,
1996)). In fuel fabrication and reprocessing facilities, all classified workers are
in Category A. In tables 4a and 4b the percentage of workers in class A and B
are presented for the different types of operation including all countries and
separately the EU countries.
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Many of the organisations have more than one operation but the workers
are not specified according to operations. Table 5 gives the number of workers
in class A and B in different countries indicating also the types of operation. In
the total number of workers in an organisation the workers are included only
once although they in the table might be included in more than one type of
operation The real number of workers, for example in decomissioning, is not
known because some of the organisations are doing several types of operations
and only the total number of workers in the organisation is given. It is also
important to note that all organisations answering the questionnaire did not
give answers to every question.
All organisations report that they have a well-defined pre-planned
arrangement for internal dose monitoring. Workers in category A are reported
by 18 organisations. Only one of these does not require medical examinations of
their category A workers. About one third of the organisations report that they
subcontract certain monitoring to outside organisations. Subcontractors are
commercial enterprises, national authorities and research institutes. In
Germany by law at least part of the measurements must be performed by
independent institutions. To investigate the purposes of monitoring three
questions were asked: Is monitoring carried out to assess individual doses for
entry onto a legal dose record, is monitoring carried out to monitor engineering
practices and standards or is monitoring carried out to reassure individual
workers that they are not receiving excessive doses? All three alternatives
included questions on the minimum dose that is aimed to be assessed and for
which radionuclides this applies. The results are presented in Fig.3.
Table 6 illustrates the information collected on the relative use of direct
(in vivo) and indirect (bioassay and personal air sampling) monitoring methods.
Both direct and indirect methods are used for assessment of individual doses.
All but one organisation give values below 2 mSv. In most organisations
monitoring is carried out to assess individual doses for entry onto a legal dose
record. Monitoring is also carried out to reassure the workers that they are not
receiving excessive doses.
When applicable, whole-body and thyroid counting is used also for special
monitoring, complemented by other methods. So far, seven organisations have
reported on uranium monitoring. For routine monitoring, both direct methods
(ie. whole-body and lung counting) and indirect methods (ie. urine monitoring,
faecal monitoring and personal air sampling (PAS)), are used. For special
monitoring, whole-body and lung counting as well as urine and faecal analyses
are used.  PAS monitoring is used for routine monitoring and urine analyses
are used for special monitoring.
12
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Fig 3.  Cumulative number of organisations specifying dose criterion below levels from 0
to 5 mSv.
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In table 6 the number of measurements done in vivo, in vitro and with
personal air samplers are given for fission and activation products and for
uranium, plutonium and thorium nuclides.  Data based on information given
both in the pre-questionnaire and the main questionnaire show that at nuclear
power plants fission and activation products are mostly monitored with whole-
body counting and tritium and/or actinides with bioassay methods.
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Routine and special monitoring
Fission and activation products
Routine monitoring is usually carried out to confirm that doses are below a
certain level (eg 6 mSv for Category B workers) or to identify unexpected
exposures. Special monitoring is performed after an incident, or is triggered for
some other reason.
Table 7 presents the chemical form or compound, assumed absorption
type and assumed Activity Median Aerodynamic Diameter (AMAD) and the
number of organisations reporting each parameter values for 60Co and 137Cs. For
60Co a minority of organisations are using 1 mm rather than 5 mm AMAD and 5
out of 6 organisations assume oxide is Type S. For 137Cs two out of 15
organisations are using 1 mm rather than 5 mm AMAD and 12 out of 15
organisations assume all compounds are Type F.
Table 8 presents the primary monitoring methods for fission and
activation products used to determine doses entered onto formal dose records
for routine monitoring and table 9 gives the corresponding information for
special monitoring . The most commonly monitored fission and activation
nuclides are 137Cs, 60Co, 131I, 125I and 3H.
Table 10 shows that 38 per cent of the organisations reporting on 60Co
monitoring use whole-body counting and 17 per cent use portal monitoring as
screening methods. Only eight organisations reported on follow up monitoring
and the most commonly used method then is whole-body counting. It can be
assumed that also those who did not report on follow up monitoring would be
using the same methods as for routine monitoring. For 137Cs  27 per cent use
whole-body counting as screening method and 7 per cent portal monitoring.
The method for follow up monitoring seems to be whole-body counting. Only
seven organisations answered this question. Apparently plans on how to handle
screening after incidents have not been defined. Direct measurement of 131I is
the most commonly used screening method (5 out of 10) and the method for
follow up monitoring is direct measurement either whole-body counting or
direct thyroid measurement. Only four organisations report on follow up
methods. For tritium, urine monitoring is the most commonly used screening
method (6 out of 10), follow up method is also urine monitoring.
The investigation levels vary from 0.5 to 350 kBq for 60Co with a median
of 10 kBq and 1 to 400 kBq for 137Cs with median 100 kBq. For 131I the
investigation levels vary from 0.5 to 50 kBq with median 10 kBq and for tritium
from 0.1 to 850 kBql-1.
14
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Fig 4. Cumulative number of organisations specifying minimum detectable amounts
below a particular level for 60Co, 137Cs and 131I.
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Information was collected on MDAs achieved by in vivo and bioassay
monitoring. For example, MDAs for in vivo measurements of 60Co and 137Cs are
mostly below 300 Bq. Figure 4 shows the MDAs and the cumulative number of
organisations specifying MDA below a particular level for 60Co, 137Cs and 131 I.
Almost all organisations use physical phantom efficiency calibrations –
computational methods are not used at all as can be seen in table 11.
Computational methods are developed at many institutions but apparently not
yet useful for organisations routinely monitoring workers. Only one
organisation trusts the calibration for thyroid measurement provided by the
manufacturer.
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Sampling
The methods for normalisation of urine samples for different elements are
shown in table 12 also showing the number of organisations using each method.
To collect excretion samples is not popular among the workers and especially
unpleasant if the collection period is 24 hours or even longer. According to this
survey most commonly used methods are not to normalise at all or to use the
creatinine method. Creatinine is produced in muscle tissue by the metabolism
of creatine phosphate. In order for the body to maintain a constant creatinine
content, the rate of creatinine excretion must equal its rate of metabolic
production. It is secreted into the urine. Creatinine clearance provides a
measure of the glomerular filtration rate (ICRP). Using the creatinine method
one sample is sufficient to calculate the daily excretion. More details are
presented in the WP3 report of the OMINEX project.
For fission products, 24 h collection is most common (7 out of 10
organisations). For tritium, out of 9 responses, not to normalise is most
common (3 organisations), 2 normalise by volume. Presumably, all also should
normalise by volume because activity concentration (Bq/litre) is required.
16
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Fig 5. Cumulative number of organisations reporting investigation levels below daily
excretion levels shown in the figure.
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The times of any potential exposures are usually not known, and so monitoring
is carried out at fixed time intervals. Table 13 presents the data collected on the
frequency of routine monitoring measurements for α− and β-emitting
radionuclides. For a particular radionuclide (or class of radionuclide),
monitoring method and frequency, the table shows the number of organisations
reporting that monitoring according to this specification is carried out, and the
corresponding number of measurements performed. As can be seen, there is no
clear consensus on monitoring intervals. For whole body monitoring, the
largest number of organisations report a 1-year monitoring interval, but
several organisations use much shorter intervals, and a significant number of
measurements are carried out with a weekly interval. Similarly, for tritium-in-
urine monitoring, five organisations use monitoring intervals of two weeks or
less while seven organisations use longer monitoring intervals. The most
common monitoring intervals for whole body are 1y (12 out of 24 organisations)
and 6 months (7 out of 24). This is rather infrequent, but this type of monitoring
intervals may be adequate if main purpose is reassurance monitoring (this
information is  however not readily available from the questionnaires). For
iodine in thyroid monitoring, there is also a very wide range of monitoring
intervals, ranging from 1 y (4 out of 17 organisations) to 1 week (1 out of 17
organisations). For tritium in urine, monitoring intervals range from 1 y (2 out
of 12) to 1 week (4 out of 12). The one week monitoring interval is unnecessarily
short. The uncertainties arising from a 1 y interval are extremely large if it is
not a task based monitoring.
Investigation levels for special monitoring
Special monitoring is performed after an incident, or is triggered for some other
reason. Information was collected on screening methods and follow-up
monitoring methods used in special monitoring. Measurements made for
screening purposes are interpreted using investigation levels, which are
specified either as amounts of activity in the body (Bq) or activity concentration
in excreta (Bq/d), or as dose levels (mSv).  For 60Co and 137Cs, whole body
counting and portal monitoring are the most commonly used screening
methods and the method for follow up monitoring is whole-body counting. For
131I, direct measurement is the most commonly used screening method and the
method for follow up monitoring is either whole-body counting or thyroid
measurement. Figure 6 shows the reported investigation levels for 60Co, 137Cs
and 131I. These are in the range 0.5 – 350 kBq for 60Co (median ~ 10 kBq) and in
the range 1 – 400 kBq for 137Cs (median ~ 100 kBq).
18
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Fig 6.  Cumulative numbers of organisations using an investigation level below the levels
given in Bq in the figure.
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For fission and activation products 12 out of 20 organisations use investigation
levels that are associated with dose, and the doses range from 0.1 to 15  mSv.
Actinides
The most commonly monitored elements are uranium, plutonium, thorium and
americium. In table 14 there is a compilation of organisations reporting
assumed absorption types and AMAD assumptions for different actinide
compounds. All organisations assume that the AMAD is 5µm for the above
mentioned nuclides.
When applicable, whole-body and thyroid counting is used also for special
monitoring, complemented by other methods. Seven organisations have
reported on uranium monitoring. For routine monitoring, both direct methods
(ie. whole-body and lung counting) and indirect methods (ie. urine monitoring,
faecal monitoring and personal air sampling (PAS)), are used. For special
monitoring, whole-body and lung counting as well as urine and faecal analyses
are used.  PAS monitoring is used for routine monitoring and urine analyses are
used for special monitoring. Only UK organisations use PAS/SAS as primary
monitoring method for actinides.
19
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Tables 19 and 20 illustrate the information collected on the relative use of
direct (in vivo) and indirect (bioassay and personal air sampling) monitoring
methods.  The indirect methods are mostly used for actinide monitoring, and
are often the only available methods for this class of radionuclides.
Uranium
Eleven organisations answered to questions on chemical compounds,
absorption types and natural versus depleted uranium(table 14). Six
organisations reported that they do depleted uranium measurements. For
U3O8, 6 out of 6 organisations assume Type S. However, this compound is
sufficiently different from Type S to give rise to significant errors in the
interpretation of urine excretion data. For UO3, UF4, UO2F2, 1 out of 3
organisations assume Type S. This is not justified; significant errors could
result in the interpretation of lung monitoring. There appears to be some
confusion as to the correct assignment of particular uranium compounds to the
default absorption types (F, M or S). Organisations should consult the
literature, and/or conduct suitable experimental studies where necessary.
Five different monitoring methods for uranium are listed in table 15. The
most commonly used methods are urine and faeces monitoring. The highest
numbers of measurements per year are reported for personal air samplers
(PAS) and static air samplers (SAS). Total number of workers as well as
numbers reported separately for class A and B for organisations using the
different methods are given in table 16.
During the last few years interest has been shown to uranium and
especially depleted uranium. Questions on uranium compounds and details of
monitoring were asked. Only five organisations responded. Only in UK
personal air samplers (PAS) are used for routine monitoring. Urine samples are
commonly used whereas only two organisations use lung or faecal monitoring
routinely. For special monitoring a combination of methods are used.
20
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Fig 7. The annual number of workers monitored for uranium directly or indirectly at
different organisations
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Figure 7 illustrates the annual number of workers monitored for
uranium directly or indirectly at different organisations. The numbers vary
from ranges of 50-100 to more than 1000.  The most common routine method is
indirect monitoring. For uranium, 24 hour collection of urine is most common
(4 out of 7 organisations).
Five organisations reported their measurement frequency of direct
uranium measurements. Three of them monitor workers once a year and two
four times per year (Table 17). Urine measurement frequency for different
organisations and the related numbers of measurements per year are given in
table 18. Three organisations of nine do urine measurements twice per year,
five four times per year and one every month. For lung monitoring the most
common monitoring interval is 1 year, three out of nine organisations use that.
For urine monitoring the most common monitoring intervals are six months (3
out of 8) and three months (4 out of 8). For faecal monitoring the most common
monitoring interval is six months (2 out of 3).
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Fig 8. Cumulative number of organisations specifying minimum detectable amounts
below the levels indicated in the figure.
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Figure 8 illustrates the difference in MDAs for lung and urine excretion
measurements for 238U. In the direct measurement the uncertainties in
calculating the daily urine excretion are avoided. Information was also collected
on urine sampling periods. About half of the organisations reported the use of
24 hour sampling for uranium-in-urine monitoring, with the remainder
carrying out normalisation by creatinine determination or by volume. The use
of 24 hour sampling eliminates uncertainties resulting from different
normalisation methods. The uncertainties involved in using creatinine for
normalisation are considered in work package 4 of the OMINEX project. The
direct method is favoured by the workers being monitored. Figure 9 shows the
cumulative number of organisations using an investigation level expressed as
mg uranium per gram of creatinine in urine.
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Fig 9.  Cumulative number of organisations using an investigation level below the levels
indicated in the figure.
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Plutonium
Tables 19 and 20 illustrate the information collected on the relative use of direct
(in vivo) and indirect (bioassay and personal air sampling) monitoring methods.
The indirect methods are mostly used for actinide monitoring, and are often the
only available methods for this class of radionuclides.
Six organisations report on plutonium monitoring. Three commonly used
methods are urine monitoring, combined urine and faeces monitoring and PAS
monitoring. One organisation reports using only faeces monitoring. PAS and
urine monitoring is used for routine monitoring and urine and faecal analyses
for special monitoring The number of workers monitored for  plutonium  at
different organisations vary from less than 20 to more than 1000 (Fig. 10). The
highest number of workers are routinely monitored indirectly.
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Fig 10. The annual number of workers monitored for plutonium directly or indirectly at
different organisations.
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All organisations report AMAD 5µm for plutonium and assume
absorption type S for the oxide. For plutonium nitrate two out of four
organisations assume type M and two out of four assume type S and one
organisation did not specify any assumed absorption type. For unknown
compounds three organisations report assuming the type S and three type M.
When urine monitoring is used, normalisation by creatinine is most
common (4 out of 9 responses) for plutonium. Two organisations normalise by
volume and one does no normalisation.
For lung monitoring, the most common monitoring interval is 1 year (2
organisations out of 4) as shown in table 21. One organisation reports
monitoring twice per year and another four times per year. For urine
monitoring, monitoring intervals range from 1 month to 1 year (no consensus).
Four organisations out of nine do it every three months. For faecal monitoring,
most common monitoring is 1 y (3 out of 5), followed by twice per year (2 out of
5).
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Americium
Six organisations reported on americium monitoring. All organisations assume
AMAD 5 µm  and type M for all compounds of americium. The methods for
americium routine monitoring are given in table 19 and for special monitoring
in table 20. PAS or urine monitoring is used for routine monitoring and lung
counting, urine and faecal analyses are used for special monitoring. Lung
measurements are used only in connection with indirect methods for both
routine and special monitoring. At one organisation more than 1000 workers
are monitored routinely using PAS.
Only less than one hundred measurements of americium per year were
reported. Many organisations did not give any number of workers. The
monitoring intervals for lung  measurements varied from two times a year to
once every two years. For urine frequency the variation was from every week
to once a year and for faeces once or twice a year. For screening and follow up
methods both direct and indirect methods are used(Table 22). A majority of
organisations use MDA as the investigation level.
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Fig 11. The annual number of workers monitored for americium directly or indirectly at
different organisations
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Thorium
Four organisations have reported on thorium monitoring. PAS monitoring is
used for routine monitoring and urine analyses are used for special monitoring.
For thorium all reporting organisations use AMAD 5 µm. Two organisations
report assumed absorption type S for oxide. One organisation assumes type M
for the nitrate. If the material is 232Th, this is incorrect. Type S is the correct
assumption. PAS monitoring is used for routine monitoring and urine analyses
are used for special monitoring. Urine monitoring is most commonly used for
thorium both for routine and special monitoring. Monitoring intervals vary
from once per year to four times a year at the five organisations supplying
information. Less than 50 measurements per year were reported to be done.
This is a very small portion of the many hundred workers involved. Also for
thorium the MDA is used as investigation level or for nose blow 0.5 Bq.
Investigation levels for special monoitoring
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Fig 12. Cumulative number of  organisations specifying MDA in Bq below the levels
marked in the figure.
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Figure 12 shows the MDA and the cumulative number of organisations
specifying MDA below a certain level for direct measurements of 238U and
241Am/Pu. Figure 14 shows the MDA (Bq/d) for indirect urine measurements
and the cumulative number of organisations specifying MDA below a certain
level for uranium, plutonium, thorium and americium.
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Fig 13. Cumulative number of organisations specifying MDA below levels indicated in
the figure as Bqd-1 for urine measurements of 235U, 238U, 238,239,240Pu and 232Th.
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Investigation levels for different screening methods in case of special
monitoring and method of follow up monitoring are given in Table 22. Urine
monitoring is most commonly used for screening. Follow up methods often
include a combination of direct and indirect measurements. To try to see a
trend in special monitoring a question to be answered was how many workers
were controlled annually by special monitoring after routine monitoring had
indicated the need. The results are given in table 23 for fission and activation
products and actinides annually from 1996 to 2000. It is not possible to see any
trend from this material. More should be known about the reasons for special
monitoring in each case.
Doses
Dose calculations are primarily done manually or using own software. Of the
commercially available dose calculation programs, most popular is LUDEP (12)
followed by IMBA  and CINDY(3) as can be seen from table 24.
Table 25 shows individual internal dose statistics for the last year before
answering the questionnaire as reported by 14 of the responding organisations.
Many of the organisations that did not answer this question can be supposed not
to have reached the 0,1 mSv level.
Both direct and indirect methods are used for assessment of individual
doses. The indirect methods are mostly used for actinide monitoring, and are
often the only available methods for this class of radionuclide.
All organisations monitor workers to assess individual doses for entry onto a
legal dose record.  A minority do it to monitor enginering practices and
standards and three thirds to reassure individual workers that they are not
receiving excessive doses. Two modes in the distributions can be noted, centred
at 0.1 mSv and 1 mSv (Fig 14). Not particularly dependent on the monitoring
purpose. For uranium, 4 out of 7 organisations report  0.1 – 15 mSv, for
plutonium, 3 out of 7 organisations, 0.1 – 6 mSv and for americium, 4 out of 11
organisations, 5 - 15 mSv.  It is not clear why there are organisations reporting
minimum doses to be aimed at smaller than 0.1 mSv.
The individual internal dose statistics for the number of cases assessed
with doses in the ranges 0.1 – 0.5 mSv, 0.5 – 1 mSv, 1 – 2 mSv, 2 – 5 mSv, 5 – 10
mSv, 10 – 20 mSv and >20 mSv for the last year prior to responding to the
questionnaire shows a maximum number of 2017 recorded doses in the lowest
range and 216, 105, 17 and 6 respectively in the following four ranges. No doses
higher than 10 mSv were reported.
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Fig 14. Minimum doses aimed to be assessed for dose records, for monitoring
engineering practices and for reassuring workers versus number of organisations.
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Fig 15. Dose levels for criteria 1 (dose could exceed) and 2 (reassurance) used by
organisations monitoring uranium indirectly .
Plutonium:
Fig 16. Dose levels for criteria 1 (dose could exceed) and 2 (reassurance) used by
organisations monitoring plutonium indirectly.
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Figure 17 shows dose investigation levels and cumulative numbers of
organisations using an investigation level below a certain level for fission
products, uranium, plutonium, thorium and americium.
Table 25 gives the individual internal dose statistics for the year before
answering the questionnaire. It can be seen that only six doses reported were
between five and ten millisieverts, all the rest below that range. The maximum
amount (2017 doses) was reported to be in the range 0,1 to 0,5 millisievert.
Fig 17. Cumulative number of organisations using investigation levels below levels from
0,1 to 15 mSv for fission products, uranium, plutonium, thorium and americium.
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4 Conclusions
The survey provides a representative coverage of the six types of operation
identified and a sufficient numbers of workers. All responses were not complete
which shows in the tables where all numbers do not add up as expected. The
material included in this report is large enough to meet the requirements of
getting a good overview of the monitoring situation today.
The majority of organisations carry out whole-body counting
measurements for 60Co, 137Cs and other fission and activation nuclides(FAP).
Fewer organisations carry out iodine-in-thyroid monitoring than FAP
monitoring. No explanation can be found in the results of the survey. For
actinides, all methods are more or less equally likely : lung, urine, faeces, PAS,
SAS, nose blow, (Portal monitor!). No particular relationship with radionuclide
was found.  There are several instances of clearly inappropriate methods being
used as nose blow screening for tritium exposures and use of  portal monitors
for actinide monitoring. The main difference between routine and special
monitoring is the use of combinations of direct and bioassay monitoring for
special monitoring. Special monitoring is also more case dependent.
A major conclusion is that, particularly for the actinides, a wide range of
approaches to monitoring are in use. There is no consensus on primary
monitoring methods. Apart from whole-body counting for fission and activation
products there is no consensus on monitoring intervals (MI).
There appears to be some confusion as to the correct assignment of
particular uranium compounds to the default absorption types (F, M or S).
Organisations should consult the literature, and/or conduct suitable
experimental studies where necessary.
All organisations monitor workers to assess individual doses for entry
onto a legal dose record. A minority do it to monitor enginering practices and
standards and three thirds to reassure individual workers that they are not
receiving excessive doses. Two modes in the distributions can be noted, centred
at 0.1 mSv and 1mSv, not particularly dependent on the monitoring purpose.
A wide range of investigation levels was found. For fission and activation
products , 12 out of 20 organisations use investigation levels that are associated
with dose, and the doses range from 0.1 to 15 (!) mSv.
Cumulative distributions show that most organisations aim to assess
doses down to 0.1 – 0.5 mSv. This is lower than is required by EURATOM
directive which indicates that doses above 1 mSv should be assessed for Cat B
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workers. From the point of view of legislative requirements, it is not necessary
to assess doses below 1 mSv. The EURATOM Directive defines exposed workers
as those workers who could receive doses in excess of the public dose limits.
This could mean that some organisations are expending unnecessary effort in
assessing doses at ~ 0.1 mSv. Some organisations might have sensitive
measurement systems for other purposes and in that case the effort is the same
assessing a dose of  0,1 or 1 mSv. The legislative requirements consider the
total dose not only the internal dose. . For fission and activation products the
external dose is normally the higher and the internal dose low in comparison.
For actinides the situation is the opposite.
The number of radiation workers in different countries is generally not
reported. The number of workers surveilled for internal doses even less. With
the resources allocated to WP 1 in the OMINEX project it was not possible to
approach every organisation in Europe with workers exposed to internal
contamination. All organisations the WP 1 questionnaire was sent to did not
respond. In some countries there are no arrangements for internal
contamination measurements. If the risk for internal contamination does not
involve very many workers there is a possibility to send people or samples to be
measured in another country. The aim of the OMINEX project was not to
evaluate this kind of arrangement. The material included in this report is large
enough to meet the requirements of getting a good overview of the monitoring
situation today.
The results of the OMINEX survey can be compared with information
published by NUREG in the United States.The internal doses divided in steps
from less than 1 mSv to 1-5, 5-10, 10-20 and more than 20 mSv show a rather
similar distribution in USA and Europe but a trend towards lower doses in
Europe as found in the OMINEX survey (Fig 18).
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OMINEX0
20
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Fig 18. Comparison of distribution of internal doses in five different ranges from the
OMINEX survey and corresponding data presented by NUREG.
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7 Tables
Table 1. Types of operation and numbers of organizations using certain types of
monitoring  for routine and special situations
Radionuclides monitored Type of  
operation 
Number of 
organisation FAP U Pu Th Am MOX
NPP 34 33 5 6 1 4 -
Reprocessing 2 2 2 2 1 2 -
Fuel fabrication 7 5 7 6 4 5 1
Decommissioning 6 5 6 6 3 6 1
Research 19 17 11 9 5 12 2
Non-nuclear 3 3 2 2 2 3 1
Table 2. Types of operation and numbers of organizations monitoring for certain
radionuclides
     Type of monitoring              Monitoring Type of  
operation 
Number
of or-
ganizati-
on
In
vivo
Bioassay SAS
PAS
Routi-
ne
Special Both
NPP 34 33 15 7 8 4 27
Reprocessing 2 2 2 - - - 1
Fuel fabrication 7 6 6 2 3 2 5
Decommis-
sioning 
6 5 6 1 2 2 5
Research 19 17 12 5 3 5 16
Non-nuclear 3 3 3 2 2 2 2
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Table 4 a.  Type of operation and percentage of workers in categories A and B (all
countries included).
Table 4 b.  Type of operation and percentage of workers in categories A and B (all EU
countries included).
No of workers A+B 
categories 
Category A workers 
(%)
Category B workers 
(%)
NPP 106 887 88 12
Fuel fabrication 11 150 100 -
Reprocessing 10 500 100 -
Research centre 26 248 65 35
Decommissioning 16 650 81 19
Non-nuclear industry 6 150 48 52
Total 117 485 84 16
No of workers  
A+B categories 
Category A workers 
(%)
Category B workers 
(%)
NPP 99 312 87 13
Fuel fabrication 11 150 100 -
Reprocessing 10 500 100 -
Research centre 26 208 65 35
Decommissioning 16 650 81 19
Non-nuclear industry 6 150 48 52
Total 109 870 83 17
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Table 6. Number of in vivo, in vitro and PAS measurements of fission and activation
products(FAP), uranium, plutonium and thorium nuclides per year.
Table 7. Assumed  60Co and 137Cs compounds, absorption types  and AMADs
in different organisations.
Element/ 
Radionuclide
Compound Assumed 
Absorption  Type 
(F,M,S)
Assumed  
AMAD (µm) 
No. of 
organisations 
Co oxide M 5 2
Co oxide S 5 5 
Co oxide not specified 1 1
Other M 1 1
Other M 5 2
Other S 1 2
Other S 5 4
60Co
Other S worst case 2
Any F 1 2
Any F 5 10
Any M 5 1
137Cs
Any not specified 1, worst 
case 
2
No of in vivo
measurements/y 
No of in vitro  
measurements/y 
No of PAS
mesurements/y 
FAP 19394 6605 -
U 1135 5210 222650 
Pu 2420 11141 372300 
Th - 39 1825
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Table 8. Primary routine monitoring methods used to determine doses entered onto
formal dose records.
                       Fission and activation products, Routine 
Nuclide
Method 137Cs 60Co 131I 125I 3H 14C 32P 35S 90Sr/
90Y
Other 
WBC
WBC+urine 
WBC+urine+faeces 
WBC+lung 
Urine
Urine+faeces 
Urine+expired air 
Lung
Quick scanner 
Thyroid monitor 
Thyroid+urine 
PAS
18
1
1
1
17
1
1
1
1
1
7
1
1
8
2
2
1
5
1
13 4
1
4 2
2
3
1
1
6
1
Table 9. Primary special monitoring methods used to determine doses entered onto
formal dose records.
       Fission and activation products, Special
Nuclide
Method 137Cs 60Co 131I 125I 3H 14C 32P 35S 90Sr/
90Y
Other
WBC
WBC+urine
WBC+urine+faeces
WBC+lung
Urine
Urine+faeces
Urine+expired air 
Lung
Quick scanner
Thyroid monitor
Thyroid+urine
PAS
15
3
1
1
14
2
2
1
1
5
1
1
9
4
3
1
5
3
13 5
1
5 5
1
6
2
3
2
1
1
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Table 10. Screening and follow up methods and investigation levels of 60Co, 137Cs, 131I and
tritium for special monitoring
Radio-
nuclide
Screening 
Method
Investigation
level,
median (range)
No. of 
 organisations 
 (% of total) 
Follow up Monitoring 
(no. of organisations using 
this method) 
Whole body 10 kBq  
(0.5-350 kBq) 
11 (38) 
Urine ? 2 (7) 
Portal >MDA,  
2000-3000 Bq 
5 (17) 
PAS 40 DACh 1 (3) 
SAS if>LD, case specific 3 (10) 
60Co
Nose blow if>LD, case specific 2 (7) 
whole body (7), 
urine+faeces (1) 
Whole body 100 kBq 
(1-400 kBq) 
8 (27) 
Urine ? 2 (7) 
Portal if > LD, 600 Bq 2 (7) 
PAS 40 DACh 1 (3) 
SAS if>LD, case specific 2 (7) 
137Cs
Nose blow if>LD, case specific 2 (7) 
whole body (7), urine (1) 
Whole body 10 kBq 
(0.5-50 kBq) 
7 (24) 
Urine ? 2 (7) 
Portal if>LD 1 (3) 
PAS  0  
SAS if>LD 1 (3) 
131I
Nose blow if>LD 1 (3) 
in vivo thyroid monitoring 
(3), urine (1) 
Urine >MDA,
0.1-850 kBq/l 
6 (21) 
Portal if>LD 2 (7) 
SAS if>LD 1 (3) 
Tritium
Nose blow if>LD 1 (3) 
urine (8) 
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Table 11. Efficiency calibration method for direct measurements.
Table 12. Normalisation of urine samples for monitoring of fission and activation
products(FAP), tritium and actinides
Measurement method Calibration method No. of
organizations 
Whole body Provided by manufacturer 
Physical phantom 
Computational method 
0
24
0
Thyroid Provided by manufacturer 
Physical phantom 
Computational method 
1
20
0
Element Normalisation method No. of organizations
By volume 0
By creatinine 3
No normalisation (24 h collection) 7
FAP except tritium
Bulked 1
By volume 2
By creatinine 1
No normalisation (24 h collection) 3
Tritium
Bulked 1
By volume 3
By creatinine 1
Uranium
No normalisation (24 h collection) 4
By volume 2
By creatinine 4
No normalisation (24 h collection) 1
Plutonium
Bulked 2
Thorium No normalisation (24 h collection) 2
No normalisation (24 h collection) 4Americium
Bulked 1
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Table 13. Monitoring intervals for direct and indirect methods for fission and activation
products.
For this material, method and  
monitoring interval range: 
Radio-nuclide Method Monitoring 
frequency 
(times/y) No. of
organisations
No. of 
 measurements/y 
1 12 6824 
2 7 2150 
4 2 480 
6 1 220 
12 1 1720 
Whole body 
52 1 8000 
1 2 20 
4 1 5 
6 1 200 
12 3 2960 
24 1 ? 
Urine (tritium) 
52 4 >3600 
2 1 >1000 
4 1 100 
Fission and 
activation
products 
except iodine 
Urine (Sr/Y) 
? 1 10 
Direct 1 4 5365 
 2 1 ? 
 4 1 100 
 12 4 2440 
 26 1 ? 
 52 1 10 
Iodine (131I)
 other 
(occasionally,
when needed, 
self checking 
etc.)
5 350 
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Table 14. Assumed actinide compounds, AMADs and absorption types in different
organisations.
Element/ 
Radionuclide
Compound Assumed 
Absorption  Type 
(F,M,S)
No. of 
organizations 
U3O8 S 6
UO2 S 7 
UO3 M 2
UO3 S 1 
UF4 M 2
UF4 S 1 
UF6 F 2
UO2F2 F 2
UO2F2 S 1 
Metallic U S 2
F 5
M 2
Uranium
all assume  
AMAD 5 µm 
Other, 
unknown 
S 4 
PuO2 S 6 
Pu(NO3)4 M 2
Pu(NO3)4 S 2 
Pu(NO3)4 not specified 1 
Unknown M 3
Plutonium 
all assume  
AMAD 5 µm 
Unknown S 3
Oxide S 2 
Nitrate M 1
Unknown S 1
Thorium 
all assume  
AMAD 5 µm 
Unknown F,M,S 1
AmO2 M 5
Am(NO3)3 M 3
Americium 
all assume  
AMAD 5 µm 
Other/ 
unknown 
M 5
Table 15. Monitoring methods and number of organisations using each method and
number of measurements per year.
Uranium
Method No of organizations Number of measurements/y 
Urine 10 5280
Faeces 4 1000
Direct/lung 10 >1135
PAS 4 222650 
SAS 2 32850
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Table 16.  Number of organisations using different methods and total number of workers
as well as numbers reported for class A and B.
Uranium
Method No of
organizations 
Total no of 
workers
No of workers in 
category A 
No of workers in 
category B 
Urine 10 267405 74819 17971
Faeces 4 96763 61461 14739
Direct/lung 10 201113 17111 9157
PAS 4 14912 10500 -
SAS 2 3470 - -
Table17.  Frequency of direct uranium measurements and number of measurements per
year
Direct measurements
Frequency 1/y
Number of
organizations
Number of 
measurements/y
1 3 125
4
Total
2
5
1010
1135
Table 18. Urine measurement frequency for different organisations and the related
numbers of measurements per year
Urine measurements, uranium 
Frequency 1/y  
Number of
organizations 
Number of
measurements/y 
2 3 1990
4 5 2090
12 1 1200
Total 9 5280
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Table 19. Routine monitoring methods for uranium, plutonium, thorium and americium
determination
Table 20. Special monitoring methods for uranium, plutonium, thorium and americium
determination
Actinides, Routine 
Nuclide
Method U Pu Th Am
Lung
Urine
Urine+faeces 
Urine+lung
Urine+air sampling 
Faeces
Faeces+urine+lung
Faeces+lung
PAS
SAS+PAS 
PAS+urine 
1
3
2
1
1
1
2
1
1
3
3
1
3
2
1
1
2
3
1
1
1
2
Actinides, Special 
Nuclide
Method U Pu Th Am
Lung
Urine
Urine+faeces 
Urine+lung
Urine+air sampling 
Faeces
Faeces+urine+lung
Faeces+lung
PAS
SAS+PAS 
PAS+urine 
WBC+bioassay 
1
4
5
2
1
1
1
9
1
1
2
1
1
3
6
1
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Table 21. Monitoring intervals of actinides using different methods
For this material, method 
and monitoring interval: 
Element Method Monitoring  
frequency 
(times/y) No. of
organizations 
No. of
measure-
ments/y 
1 3 125Lung
4 2 1010
2 3 1990
4 5 2090
Urine
12 1 1200
1 1 ? 
Uranium
Faeces
2 2 1000
1 2 1300
2 1 1000
Lung
4 1 50
1 2 306
2 2 1000
4 4 5570
Urine
12 1 4200
1 3 341
Plutonium 
Faeces
2 2 1000
Americium Lung 0.5 1 25
1 1 ? 
2 1 40
Urine 1 1 4
2 2 ? 
12 1 ? 
52 1 ? 
Faeces 1 1 4
2 1 ? 
Lung 1 1 ? 
1 2 35Urine
4 1 4
Thorium 
Faeces 1 1 6
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Table 22.  Screening and follow up methods and investigation levels used for special
monitoring
Lung if > MDA 3 (10) 
Urine values not in same 
units 
5 (17) 
Faeces if>MDA 3 (10) 
PAS 1-40DACh 2 (7) 
SAS if>MDA, 1.2DACh 3 (10) 
Nose blow if>MDA, 0.2-6 Bq 3 (10) 
Uranium
Portal if>MDA 1 (3) 
lung+urine+faeces (2), 
lung+urine (1), 
lung (1), urine (4) 
Lung if>MDA 2 (7) 
Urine if>MDA, 0.5-
0.8mBq/d 
5(17)
Faeces if>MDA, 8 mBq/d 4 (14) 
PAS 1.2-40 DACh 2 (7) 
SAS if>MDA 2 (7) 
Nose blow if>MDA, 0.2-0.5Bq 4 (14) 
Plutonium 
Portal if>MDA 1 (3) 
lung+urine+faeces (1), 
urine + faeces (2), 
lung (1), faeces (1) 
Urine if>MDA, 0.5mBq/d 3 (10) 
Faeces if>MDA 1 (3) 
PAS 40 DACh 1 (3) 
SAS case specific 1 (3) 
Thorium 
Nose blow 0.5 Bq 1 (3) 
urine (3) 
Americium Lung if>MDA 2 (7) lung+urine+faeces (1), 
faeces (1), 
head+urine (1) 
Radio-
nuclide 
No. of 
organiza
tions 
No. of
persons/y 
year 1996 
No. of
persons/y 
year 1997 
No. of 
persons/y 
year 1998 
No. of 
persons/y 
year 1999 
No. of 
persons/y 
year 2000 
Fission 
products 
21 567 1269 887 830 1607
Uranium 7 134
Plutonium 8 55 120 514 294 765
Thorium 4 21 60 21 0 0
Americium 11 74 118 234 164 112
Table 23. Number of persons controlled by special monitoring annually from year 1996 to
year 2000 for fission products and actinides
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Table 24. Methods of dose calculation
Organisation Manual
calculation
Own
software 
LUDEP CINDY IMBA Other method 
1      RETEX 
2 Yes    Yes  
3 Yes      
4  Yes   Yes  
5 Yes  Yes   German guideline 
6  Yes Yes Yes  CALIN 
7  Yes    IMIE 
8  Yes Yes Yes  IMI 
9 Yes      
10  Yes     
11 Yes  Yes    
12 Yes  Yes    
13 Yes Yes Yes   IMIE 
14 Yes  Yes   MONDAL/MONDES 
15 Yes  Yes    
16  Yes Yes Yes   
17      ICRP-30 
model/Nuclear-Data
18 Yes      
19  Yes     
20 Yes  Yes  Yes  
21 Yes      
22 Yes  Yes    
23 Yes Yes    RETEX 
24 Yes Yes Yes    
25  Yes    INDAC 
26  Yes     
27       
Total 15 12 12 3 3 10
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Table 25.  Individual internal dose statistics for the last year
Organiza-
tion
0,1-0,5
(mSv)
0,5-1
(mSv)
1-2
(mSv)
2-5
(mSv)
5-10
(mSv)
10-20
 (mSv) 
>20
(mSv)
1 10 3 1
2 1374 100 44 5 0 0 0
3
4 198 18 8 3 1 0 0
5
6 1 1
7 4 2
8 50 3 5 0 0
9 1
10
11 11 1
12 18 3 0 0 0 0 0
13 3
14
15
16 244 42 25 5 0 0 0
17 6 3 1
18 0 0 0 0 0 0 0
19 15 15 16 2 0 0 0
20 93 14 6 1 0 0 0
21
22 0 0 0 0 0 0 0
23 0
24
25
26
27 5
TOTAL 2017 216 105 17 6 0 0
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OMINEX     24.7.2001  ANNEX 1
Pre-questionnaire to determine scope of monitoring programme 
1.  Name :  _________________________  Organisation :  _________________________ 
2.  In which format would you prefer to receive the OMINEX questionnaire ? 
Word 97 document by e-mail __  
Wordperfect 8.0 document by e-mail __  
Text (.txt) file by e-mail  __  
Hard copy by post  __  
 Other (specify) ________________________________ 
3.  Type of Operation  Remarks
Nuclear power plant   __    
Reprocessing   __   
Fuel fabrication   __   
Decommissioning   __   
Research centre   __   
Non-nuclear industry   __   
4.  Type of monitoring 
In vivo monitoring  __  
Bioassay (urine, faeces, etc) monitoring __  
Air sampling __  
5.  Radionuclides Monitored 
Fission/Activation products __   
U   __   
Th                    __    
Pu   __     
Am   __     
MOX   __     
Other actinides  __    
6.  Does your organisation carry out: 
Routine monitoring  __  
Special (incident) monitoring __  
51
STUK-A203
     ANNEX 2
QUESTIONNAIRE ON INTERNAL DOSE  
MONITORING PROGRAMMES 
Instructions for use 
Use the right hand SCROLL BAR (or the middle button/wheel on your mouse) to scroll through the 
document.
Use the PageUp / PageDown keys (or TAB and SHIFT TAB) to move between fields.
Click on the shaded fields to make an entry. 
To copy sections of the questionnaire, first open the Forms Toolbar in MS Word 
(View/Toolbars/Forms), and then click on the Protect Form icon to unlock the form. 
OMINEX (Optimisation of Monitoring for Internal Exposure) is a 3-year project funded by the 
European Commission within its 5
th
 Framework Programme. The aim of the project is to develop 
advice on occupational exposure monitoring programmes.  The result should be improvements in the 
accuracy and reliability of assessed internal doses, better use of available resources, and reduction in 
costs of monitoring. The project is being carried out by a consortium of research/advisory 
organisations [NRPB (UK), IPSN (France), STUK (Finland), SCK-CEN (Belgium), CEA (France)] 
and nuclear industry organisations [EdF (France), TVONS (Finland)]. The UK nuclear industry is 
also providing a significant input.
With this questionnaire, we aim to collect comprehensive information on current monitoring practice 
throughout the EU, in the countries that are associated to the EU, and in other countries with 
significant nuclear power programmes. We hope you will spend some time to complete those parts of 
the questionnaire that are relevant to your area of work. All information collected will be kept 
anonymous. The results of the project will be presented  at a Training Course that will be held in late-
2003. All those contributing to this survey will be provided with information on the Training Course 
during the final year of the project. 
Thank you for you co-operation. Assistance in completing this questionnaire can be obtained from : 
tua.rahola@stuk.fi
More information on OMINEX can be found at : 
http://dbs.cordis.lu/fep/FP5/FP5_PROJl_search.html
or obtained from the Scientific Coordinator :  
george.etherington@nrpb.org.uk . 
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CONTENTS 
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Note.
You will be sent only those sections that are relevant to your work 
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SECTION 1, GENERAL 
Name:
Position:
Organisation: 
Country:
Type of Operation Complete sections : Remarks 
Nuclear power plant  
1, A2, 4
Reprocessing    
1, A2, A3, 4
Fuel fabrication     
1, A2, A3, 4
Decommissioning    
1, A2, A3, 4
Research centre    
1, A2, A3, 4
Non-nuclear industry    
1, A2, A3, 4
54
STUK-A203
Number of workers 
 Number of classified workers 
 Number of non-classified workers 
 Number in category A 
 Number in category B  
 Number of permanent  staff 
 Number of contract staff  
Use appropriate classification. Category A and B are defined in article 25 of Directive 
96/29/EURATOM. Enter “ - ” if not applicable. 
Medical examination for radiation work ?
6-monthly
Annually
Once every two years 
Other (specify)
Monitoring Practice 
Does your organisation have well-defined, pre-planned arrangements
for internal dose monitoring ? ?
If NO, please respond to this questionnaire by providing information on typical monitoring 
regimes. 
Does your organisation sub-contract some of its monitoring to other  
organisations ?   ?
If YES, please describe, and give contact information : 
Purposes of monitoring 
Is monitoring carried out to assess individual doses for entry
onto a legal dose record ? ?
If YES, what is the minimum dose that you aim 
to assess for this purpose? 
mSv
For which radionuclides does this apply ? 
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Is monitoring carried out to monitor engineering  
practices and standards ? ?
If YES, what is the minimum dose that you aim 
to assess for this purpose? 
mSv
For which radionuclides does this apply? 
Is monitoring carried out to reassure individual workers that  
they are not receiving excessive doses ?  ?
If YES, what is the minimum dose that you aim 
to assess for this purpose ? 
mSv
For which radionuclides does this apply ? 
A2. FISSION & ACTIVATION PRODUCTS 
Radionuclide Monitored ? 
(Y/N)
Chemical
Form or
Compound
Assumed
Absorption
Type
1
Assumed
AMAD
2
(?m)
60
Co ?
137
Cs ?
125
I ?
131
I ?
3
H ?
14
C ?
32
P ?
35
S ?
90
Sr/
90
Y ?
Other (specify) 
?
?
?
1. F, M or S (or D, W, or Y), or enter specific parameter values (eg fr, sr, ss) if used 
2. AMAD – Activity Median Aerodynamic Diameter 
What (if any) assumptions are made about the absorption of ultrafine or soluble components of 
these materials ?  
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Primary monitoring method(s) used to determine doses entered onto formal dose record  
(eg. PAS, lung monitoring, urine, faeces, etc.) 
Monitoring method(s) Radionuclide
Routine monitoring Incident (special) monitoring 
60
Co
137
Cs
125
I
131
I
3
H
14
C
32
P
35
S
90
Sr/
90
Y
Other (specify) 
Note.  If different techniques are used depending on magnitude of dose, please give this information 
in the table 
A2. FISSION & ACTIVATION PRODUCTS 
A2.1 ROUTINE MONITORING 
Purposes of routine monitoring 
Is routine monitoring carried out  : 
To assess individual doses for entry  
onto a legal dose record ? ?
To trigger special investigations or
monitoring ?  ?
A2. FISSION & ACTIVATION PRODUCTS 
A2.1 ROUTINE MONITORING 
A2.1.1 DIRECT (IN VIVO) MONITORING 
Number of persons measured each year 
 none   
 < 20   
 20 -50   
 50 -100   
 100 -200   
 200 -500   
 500-1000   
 >1000   
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Criteria for selecting individuals for monitoring 
Anticipated/possible that dose could exceed * mSv/year 
Reassurance that dose does not exceed * mSv/year 
Work with monitored radionuclide exceeds * % of work time
Specific risk assessment (eg related to activity or containment levels)
Other (specify) 
* Enter as appropriate 
 All meeting these criteria  
 Representatives from working groups 
 Random selection  
WHOLE BODY ?
Minimum detectable activity
Radionuclides monitored 
60
Co Bq
137
Cs Bq
90
Sr/
90
Y Bq
gross gamma
Bq
Other (specify) Bq
Preparation of person for in vivo measurement ?
 Shower 
Only if : 
       
 Wear clean clothing        
  Number of measurements 
 Weekly       
 Monthly       
 3-monthly       
 6-monthly       
 Annually        
 Other (specify)        
Efficiency calibration method 
 Provided by manufacturer 
 Phantom 
 Numeric phantom 
 Other (specify)        
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THYROID ?
   
   
   
  Minimum detectable activity 
131
I Bq
  Number of measurements 
  Weekly       
  Monthly       
  3-monthly       
  6-monthly       
  Annually        
  Other (specify)        
Efficiency calibration method 
 Provided by manufacturer 
 Phantom 
 Numeric phantom 
 Other (specify)        
Minimum detectable activity
PORTAL MONITOR ? Bq
  Number monitored each year 
 entrance 
 exit       
Efficiency calibration method 
 Provided by manufacturer 
 Phantom 
 Numeric phantom 
 Other (specify)        
A2. FISSION & ACTIVATION PRODUCTS 
A2.1 ROUTINE MONITORING 
A2.1.2 INDIRECT (BIOASSAY) MONITORING 
Number of persons measured each year 
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        none   
 < 20   
 20 -50   
 50 -100   
 100 -200   
 200 -500   
 500-1000   
      >1000   
Criteria for selecting individuals for monitoring 
Anticipated/possible that dose could exceed * mSv/year 
Reassurance that dose does not exceed * mSv/year 
Work with monitored radionuclide exceeds * % of work time
Specific risk assessment (eg related to activity or containment levels)
Other (specify) 
* Enter as appropriate 
 All meeting these criteria  
 Representatives from working groups 
 Random selection  
SAMPLING
Urine samples: Fission and Activation Products ?
 Fixed volume ? 
 Variable volume (eg single voiding) ? Volume =      
 Normalised to 24 h by creatinine content ? 
 Normalised to 24 h by volume ? 
 Total collection of 24-hour sample ? 
 Urine samples taken over * days and 
bulked together ? 
 Other sampling protocol (specify) 
Faecal samples: Fission and Activation Products ?
 Single voiding ? 
 Total collection for 24 hours 
 Samples taken over       * days and bulked together ? 
 Other sampling protocol (specify) 
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 Sampling at WORK ONLY   
HOME ONLY   
or HOME+WORK   
* Enter value 
MONITORING
  Minimum detectable activity 
For urine sampling interval, enter U in box 
For faecal sampling interval, enter F in box 
  Minimum detectable activity 
90
Sr/
90
Y in urine ? Bq/d
90
Sr/
90
Y in faeces ? Bq/d
  Number of measurements 
 Weekly 
 Monthly 
 3-monthly 
 6-monthly 
 Annually 
 Other (specify)      
For urine sampling interval, enter U in box 
For faecal sampling interval, enter F in box 
  Minimum detectable activity 
gross beta, urine ? Bq/d
gross beta, faeces ? Bq/d
gross gamma, urine ? Bq/d
gross gamma, faeces ? Bq/d
  Number of measurements 
 Weekly 
 Monthly 
 3-monthly 
 6-monthly 
 Annually 
 Other (specify)      
For urine sampling interval, enter U in box 
For faecal sampling interval, enter F in box 
  Minimum detectable activity 
Other (specify) ? Bq/d
  Number of measurements 
 Weekly 
 Monthly 
 3-monthly 
 6-monthly 
 Annually 
 Other (specify)      
61
STUK-A203
A2. FISSION & ACTIVATION PRODUCTS 
A2.2 INCIDENT (SPECIAL) MONITORING 
This section only requests information that is specific to incident monitoring. Please ensure that 
the previous section (A2.1) is completed as fully as possible. 
Number of persons monitored during each of the last 5 years in 1996 
in 1997 
in 1998 
in 1999 
in 2000 
Screening methods and indicators used to initiate internal monitoring : 
Are the investigation levels (used to trigger/initiate follow-up monitoring) 
associated with a dose level ?    ?
Dose Investigation level : 
mSv
% of ALI 
Investigation Levels / units (eg nose blow activity / Bq) 
Screening method 
Radio-
nuclide
SAS PAS Nose 
blow / 
nasal
smear 
Whole
body or 
lung
counting
Portal
monitor
Urine Faeces 
60
Co
137
Cs
125
I
131
I
3
H
14
C
32
P
35
S
90
Sr/
90
Y
Other
          Units 
Note.  If the investigation level is any measurement above the minimum detectable amount (however 
defined), enter “> MDA” 
Other criteria used to trigger follow-up monitoring (eg a particular event) ? 
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Procedure after investigation level exceeded? 
Intervention level 
mSv
% of ALI 
Procedure after intervention level exceeded (eg medical intervention)? 
Remarks 
Follow up monitoring 
Follow up monitoring Radio-
nuclide Monitoring
method(s) 
Measurements made on : 
(days after intake) 
(eg day 1, 3, 5, 30) 
OR No. of 
measure-
ments 
Start/end
(days after 
intake) 
(eg day 1 to
day 60) 
60
Co
137
Cs
125
I
131
I
3
H
14
C
32
P
35
S
90
Sr/
90
Y
Other
Note : If necessary, give typical values 
A3. ACTINIDES 
Actinides Monitored 
 U    Complete A3.1
 Th    Complete A3.2
 Pu    Complete A3.3
 Am    Complete A3.4
 MOX    Complete A3.5   
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Other    Complete A3.6
A3.1 URANIUM 
Chemical
Compound
Assumed
AMAD (?m)
Assumed Absorption 
Type (F,M,S) 
(or Inhalation Class, 
D,W,Y)
OR Absorption  
parameters used 
(fr, sr, ss, fb, sb)
Ammonium diuranate (ADU) 
Uranyl nitrate 
Uranium peroxide 
Uranium tributyl phosphate 
UO2F2
UF4
UF6
UO3
U3O8
UO2
metallic U 
Other (specify) 
Unknown 
What (if any) assumptions are made about the absorption of ultrafine or soluble components of 
these materials ?  
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Enriched ? Chemical
Compound
Natural
?
(Y/N)
Depleted
?
(Y/N)
< 3.5 wt%  3.5 – 50 wt% > 50 wt% 
Ammonium diuranate 
(ADU)
? ? ? ? ?
Uranyl nitrate ? ? ? ? ?
Uranium peroxide ? ? ? ? ?
Uranium tributyl phos-
phate
? ? ? ? ?
UO2F2 ? ? ? ? ?
UF4 ? ? ? ? ?
UF6 ? ? ? ? ?
UO3 ? ? ? ? ?
U3O8 ? ? ? ? ?
UO2 ? ? ? ? ?
metallic U ? ? ? ? ?
Other (specify) ? ? ? ? ?
Unknown ? ? ? ? ?
Primary monitoring method(s) used to determine doses entered onto formal dose record  
(eg. PAS, lung monitoring, urine, faeces, etc.) 
Monitoring method(s) Chemical
Compound Routine monitoring Incident (special) monitoring 
Ammonium 
diuranate (ADU)
Uranyl nitrate
Uranium peroxide
Uranium tributyl 
phos-phate
UO2F2
UF4
UF6
UO3
U3O8
UO2
metallic U
Other (specify) 
Unknown 
Note.  If different techniques are used depending on magnitude of dose, please give this information 
in the table 
A3.1 URANIUM 
A3.1.1 ROUTINE MONITORING 
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Purposes of routine monitoring 
Is routine monitoring carried out  : 
To assess individual doses for entry  
onto a legal dose record ? ?
To trigger special investigations or
monitoring  ?  ?
Note : If necessary, duplicate the following sections and complete separately for each material. 
A3.1 URANIUM 
A3.1.1 ROUTINE MONITORING 
A3.1.1.1 DIRECT (IN VIVO) MONITORING 
Number of persons measured each year 
        none   
 < 20   
 20 -50   
 50 -100   
 100 -200   
 200 -500   
 500-1000   
      >1000   
Criteria for selecting individuals for monitoring 
Anticipated/possible that dose could exceed * mSv/year 
Reassurance that dose does not exceed * mSv/year 
Work with monitored radionuclide exceeds * % of work time
Specific risk assessment (eg related to activity or containment levels)
Other (specify) 
* Enter as appropriate 
 All meeting these criteria  
 Representatives from working groups 
 Random selection  
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  Minimum detectable activity 
LUNG  ? Bq 235U
Bq
238
U
  Number of measurements 
 Weekly       
 Monthly       
 3-monthly       
 6-monthly       
 Annually        
 Other (specify)        
Efficiency calibration method 
 Provided by manufacturer 
 Phantom 
 Numeric phantom 
 Other (specify)        
A3.1 URANIUM 
A3.1.1 ROUTINE MONITORING 
A3.1.1.2 INDIRECT (BIOASSAY) MONITORING 
Number of persons measured each year 
        none   
 < 20   
 20 -50   
 50 -100   
 100 -200   
 200 -500   
 500-1000   
      >1000   
Criteria for selecting individuals for monitoring 
Anticipated/possible that dose could exceed * mSv/year 
Reassurance that dose does not exceed * mSv/year 
Work with monitored radionuclide exceeds * % of work time
Specific risk assessment (eg related to activity or containment levels)
Other (specify) 
* Enter as appropriate 
 All meeting these criteria  
 Representatives from working groups 
 Random selection  
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Measurements   
 Total uranium ? 
 Measurement technique (eg gross alpha)? 
 Isotope specific ? 
Minimum detectable activity 
URINE MONITORING  ? Bq/d (234U)
Bq/d (
235
U)
Bq/d (
238
U)
OR nanogram/d (total U) 
Urine samples    
 Fixed volume ? Volume =      
 Variable volume (eg single voiding) ? 
 Normalised to 24 h by creatinine content ? 
 Normalised to 24 h by volume ? 
 Total collection of 24-hour sample ? 
 Urine samples taken over * days and 
bulked together ? 
 Other sampling protocol (specify) 
 Sampling at WORK ONLY   
HOME ONLY   
or HOME+WORK   
* Enter value 
Number of measurements 
 Weekly 
 Monthly 
 3-monthly 
 6-monthly 
 Annually 
 Other (specify) 
Minimum detectable activity 
FAECAL MONITORING  ? Bq/d (234U)
Bq/d (
235
U)
Bq/d (
238
U)
OR nanogram/d (total U) 
Faecal samples   
 Single voiding ? 
 Total collection for 24 hours 
 Samples taken over      * days and bulked together? 
 Other sampling protocol (specify) 
 Sampling at WORK ONLY   
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HOME ONLY   
or HOME+WORK   
* Enter value 
  Number of measurements 
 Weekly       
 Monthly       
 3-monthly       
 6-monthly       
 Annually        
 Other (specify)        
A3.1 URANIUM 
A3.1.1 ROUTINE MONITORING 
A3.1.1.3 PERSONAL AIR SAMPLING 
Number of persons measured each year 
        none   
 < 20   
 20 -50   
 50 -100   
 100 -200   
 200 -500   
 500-1000   
      >1000   
Criteria for selecting individuals for monitoring 
Anticipated/possible that dose could exceed * mSv/year 
Reassurance that dose does not exceed * mSv/year 
Work with monitored radionuclide exceeds * % of work time
Specific risk assessment (eg related to activity or containment levels)
Other (specify) 
* Enter as appropriate 
 All meeting these criteria  
 Representatives from working groups 
 Random selection  
Minimum detectable activity 
PERSONAL AIR SAMPLING  ? Bq (total U) 
OR
Bq/d (
235
U)
Bq/d (
238
U)
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Number of measurements 
 Daily 
 Weekly 
 Monthly 
 Other (specify) 
Information on PAS programme :  
 Sampler type 
 Is the TOTAL or the RESPIRABLE fraction measured? 
 Flow rate 
 Assumed breathing rates  
Protection factors when Personal Protective Equipment (PPE) used 
Type of PPE Protection factor 
            
            
Measurement :  GROSS ALPHA  
or SPECTROMETRIC  
Are PAS results used for individual dose assessments ? ?
Are PAS samples bulked together before measurement ? ?
If so how many, or over what time period ? 
Minimum detectable activity 
STATIC AIR SAMPLING ? Bq (total U) 
OR
Bq/d (
235
U)
Bq/d (
238
U)
  Number of measurements 
 Daily        
 Weekly       
 Monthly       
 Other (specify)        
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Information on SAS programme :  
 Sampler type 
 Flow rate 
 Assumed breathing rates 
 Measurement : GROSS ALPHA 
                        or SPECTROMETRIC 
 Are SAS results used for individual dose assessments ? ?
 If so, is a fixed PAS/SAS ratio assumed ? ?
 PAS:SAS ratio 
A3.1 URANIUM 
A3.1.1 ROUTINE MONITORING 
A3.1.1.4 COMBINATION OF MONITORING METHODS 
 If a combination of monitoring methods is used, please explain briefly how the 
monitoring programme is organised (For example ”Daily PAS samples are taken, and 24-hour 
urine samples are taken for the same individuals every 3 months”) : 
      
A3.1 URANIUM 
A3.1.2 INCIDENT (SPECIAL) MONITORING 
This section only requests information that is specific to incident monitoring. Please ensure that 
the previous section (A3.1.1) is completed as fully as possible. 
Number of persons monitored during the last year 
Screening methods and indicators used to initiate internal monitoring : 
Are the investigation levels (used to trigger/initiate 
follow-up monitoring) associated with a dose level ? ?
Dose investigation level : mSv
% of ALI
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Investigation Levels / units (eg nose blow activity / Bq) 
Screening method 
Uranium
compound
SAS PAS Nose 
blow / 
nasal
smear 
Lung
Counting
Portal
monitor
Urine Faeces 
Ammonium 
diuranate
(ADU)
                                          
Uranyl 
nitrate
                                          
Uranium 
peroxide
                                          
Uranium 
tributyl phos-
phate
                                          
UO2F2                                           
UF4                                           
UF6                                           
UO3                                           
U3O8                                           
UO2                                           
metallic U                                           
Other
(specify)
                                          
Unknown                                           
          Units                                           
Note.  If the investigation level is any measurement above the minimum detectable amount (however 
defined), enter “> MDA” 
Other criteria used to trigger follow-up monitoring (eg a particular event) ? 
      
Procedure after investigation level exceeded? 
Intervention level  
 mSv 
% of ALI 
Procedure after intervention level exceeded (eg medical intervention) ? 
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Remarks 
      
Follow up monitoring 
Follow up monitoring Uranium
compound
Monitoring
method(s) 
Measurements made on : 
(days after intake) 
(eg day 1, 3, 5, 30) 
OR No. of 
measure-
ments 
Start/end
(days after 
intake) 
(eg day 1 to
day 60) 
Ammonium 
diuranate
(ADU)
Uranyl  
nitrate
Uranium 
peroxide
Uranium 
tributyl phos-
phate
UO2F2
UF4
UF6
UO3
U3O8
UO2
metallic U
Other
(specify)
Unknown 
Note : If necessary, give typical values. 
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A3.3 PLUTONIUM 
Chemical
Compound
Assumed AMAD 
(?m)
Assumed Absorption 
Type (F,M,S) 
(or Inhalation Class, 
D,W,Y)
OR Absorption  
parameters used  
(fr, sr, ss, fb, sb)
PuO2
Pu(NO3)4 (pure) 
Pu(NO3)4
(+ corrosion  
products)
Other (specify) 
Unknown 
What (if any) assumptions are made about the absorption of ultrafine or soluble components of 
these materials ?  
Chemical
Compound
238
Pu
(Y/N)
239,240
Pu
(Y/N)
241
Pu
(Y/N)
238,239,240
Pu : 
241
Am ratio
238,239,240
Pu : 
241
Pu ratio 
PuO2 ? ? ?
Pu(NO3)4 (pure) ? ? ?
Pu(NO3)4
(+ corrosion  
products)
? ? ?
Other (specify) ? ? ?
Unknown 
? ? ?
Primary monitoring method(s) used to determine doses entered onto formal dose record  
(eg. PAS, lung monitoring, urine, faeces, etc.) 
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Monitoring method(s) Chemical
Compound Routine monitoring Incident (special) monitoring 
PuO2
Pu(NO3)4 (pure) 
Pu(NO3)4
(+ corrosion 
products)
Other (specify)
Unknown 
Note.  If different techniques are used depending on magnitude of dose, please give this information 
in the table 
A3.3 PLUTONIUM 
A3.3.1 ROUTINE MONITORING 
Purposes of routine monitoring 
Is routine monitoring carried out  : 
To assess individual doses for entry  
onto a legal dose record  ? ?
To trigger special investigations or
monitoring ?  ?
Note : If necessary, duplicate the following sections and complete separately for each material 
A3.3 PLUTONIUM 
A3.3.1 ROUTINE MONITORING 
A3.3.1.1 DIRECT (IN VIVO) MONITORING 
Number of persons measured each year 
 none   
 < 20   
 20 -50   
 50 -100   
 100 -200   
 200 -500   
 500-1000   
 >1000   
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Criteria for selecting individuals for monitoring 
Anticipated/possible that dose could exceed * mSv/year 
Reassurance that dose does not exceed * mSv/year 
Work with monitored radionuclide exceeds * % of work time
Specific risk assessment (eg related to activity or containment levels)
Other (specify) 
* Enter as appropriate 
 All meeting these criteria  
 Representatives from working groups 
 Random selection  
  Minimum detectable activity 
LUNG ? Bq 238Pu
Bq
239,240
Pu
Are
241
Am measurements performed  
to assess Pu lung content ? 
?       Bq 241Am
  Number of measurements 
 Weekly       
 Monthly       
 3-monthly       
 6-monthly       
 Annually        
 Other (specify)        
Efficiency calibration method 
 Provided by manufacturer 
 Phantom 
 Numeric phantom 
 Other (specify)        
A3.3 PLUTONIUM 
A3.3.1 ROUTINE MONITORING 
A3.3.1.2 INDIRECT (BIOASSAY) MONITORING 
Number of persons measured each year 
 none   
 < 20   
 20 -50   
 50 -100   
 100 -200   
 200 -500   
 500-1000   
 >1000   
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Criteria for selecting individuals for monitoring 
Anticipated/possible that dose could exceed * mSv/year 
Reassurance that dose does not exceed * mSv/year 
Work with monitored radionuclide exceeds * % of work time
Specific risk assessment (eg related to activity or containment levels)
Other (specify) 
* Enter as appropriate 
 All meeting these criteria  
 Representatives from working groups 
 Random selection  
Minimum detectable activity 
URINE MONITORING ?       Bq/d (238Pu)
Bq/d (
239,240
Pu)
Urine samples    
 Fixed volume ? Volume =      
 Variable volume (eg single voiding) ? 
 Normalised to 24 h by creatinine content ? 
 Normalised to 24 h by volume ? 
 Total collection of 24-hour sample ? 
 Urine samples taken over * days and 
bulked together ? 
 Other sampling protocol (specify) 
 Sampling at WORK ONLY   
HOME ONLY   
or HOME+WORK   
* Enter value 
  Number of measurements 
 Weekly       
 Monthly       
 3-monthly       
 6-monthly       
 Annually        
 Other (specify)        
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Minimum detectable activity 
FAECAL MONITORING ?       Bq/d (238Pu)
Bq/d (
239,240
Pu)
Faecal samples    
 Single voiding? 
 Total collection for 24 hours 
 Samples taken over      * days and bulked 
together ? 
 Other sampling protocol (specify) 
 Sampling at WORK ONLY   
HOME ONLY   
or HOME+WORK   
* Enter value 
  Number of measurements 
 Weekly       
 Monthly       
 3-monthly       
 6-monthly       
 Annually        
 Other (specify)        
A3.3 PLUTONIUM 
A3.3.1 ROUTINE MONITORING 
A3.3.1.3 PERSONAL AIR SAMPLING 
Number of persons measured each year 
 none   
 < 20   
 20 -50   
 50 -100   
 100 -200   
 200 -500   
 500-1000   
 >1000   
Criteria for selecting individuals for monitoring 
Anticipated*/possible* that dose could exceed * mSv/year 
Reassurance that dose does not exceed * mSv/year 
Work with monitored radionuclide exceeds * % of work time
Specific risk assessment (eg related to activity or containment levels)
Other (specify) 
* Delete / enter as appropriate 
 All meeting these criteria  
 Representatives from working groups 
 Random selection  
78
STUK-A203
Minimum detectable intake 
PERSONAL AIR SAMPLING ?      Bq (Pu-alpha) 
OR
Bq (
238
Pu)
Bq (
239,240
Pu)
  Number of measurements 
 Daily        
 Weekly       
 Monthly       
 Other (specify)        
Information on PAS programme :  
 Sampler type 
 Is the TOTAL or the RESPIRABLE fraction measured? 
 Flow rate 
 Assumed breathing rates  
Measurement :  GROSS ALPHA  
or SPECTROMETRIC  
Are PAS results used for individual dose assessments ?  ?
Are PAS samples bulked together before measurement ?  ?
If so how many, or over what time period ? 
Protection factors when Personal Protective Equipment (PPE) used 
Type of PPE Protection factor 
            
            
Minimum detectable intake 
STATIC AIR SAMPLING ?       Bq (Pu-alpha) 
   OR 
Bq (
238
Pu)
Bq (
239,240
Pu)
  Number of measurements 
 Daily        
 Weekly       
 Monthly       
 Other (specify)        
79
STUK-A203
Information on SAS programme :  
 Sampler type 
 Flow rate 
 Assumed breathing rates 
 Measurement : GROSS ALPHA 
                        or SPECTROMETRIC 
 Are SAS results used for individual dose assessments ?  ?
 If so, is a fixed PAS/SAS ratio assumed ?  ?
 PAS:SAS ratio 
A3.3 PLUTONIUM 
A3.3.1 ROUTINE MONITORING 
A3.3.1.4 COMBINATION OF MONITORING METHODS 
 If a combination of monitoring methods is used, please explain briefly how the 
monitoring programme is organised (For example ”Daily PAS samples are taken, and 24-hour 
urine samples are taken for the same individuals every 3 months”) : 
      
A3.3 PLUTONIUM 
A3.3.2 INCIDENT (SPECIAL) MONITORING 
This section only requests information that is specific to incident monitoring. Please ensure that 
the previous section (A3.3.1) is completed as fully as possible. 
Number of persons monitored during each of the last 5 years in 1996 
in 1997 
in 1998 
in 1999 
in 2000 
Screening methods and indicators used to initiate internal monitoring : 
Are the investigation levels (used to trigger/initiate follow-up monitoring) 
associated with a dose level ?    ?
Dose Investigation level : 
mSv
% of ALI 
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Investigation Levels / units (eg nose blow activity / Bq) 
Screening method 
Chemical
compound
SAS PAS Nose 
blow / 
nasal
smear 
Lung
Counting
Portal
monitor
Urine Faeces 
PuO2
Pu(NO3)4
(pure)
Pu(NO3)4
(+corrosion  
products)
Other
(specify)
Unknown 
         Units
Note.  If the investigation level is any measurement above the minimum detectable amount (however 
defined), enter “> MDA” 
Other criteria used to trigger follow-up monitoring (eg a particular event) ? 
      
Procedure after investigation level exceeded? 
      
Intervention level 
mSv
% of ALI 
Procedure after intervention level exceeded (eg medical intervention) ? 
Remarks 
Follow up monitoring 
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Follow up monitoring Chemical
compound
Monitoring
method(s) 
Measurements made on : 
(days after intake) 
(eg day 1, 3, 5, 30) 
OR No. of 
measure-
ments 
Start/end
(days after 
intake) 
(eg day 1 to
day 60) 
PuO2
Pu(NO3)4
(pure)
Pu(NO3)4
(+corrosion 
products)
Other
(specify)
Unknown 
Note : If necessary, give typical values. 
Note : If necessary, give typical values 
A3.6 OTHER ACTINIDES 
Please duplicate section A3.6 if necessary 
Radionu
clide
Chemical
Compound
Assumed
AMAD
(?m)
Assumed Absorption 
Type (F,M,S) 
(or Inhalation Class, 
D,W,Y)
OR Absorption  
parameters used  
(fr, sr, ss, fb, sb)
Unknown 
What (if any) assumptions are made about the absorption of ultrafine or soluble components of 
these materials ?  
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Radionu
clide
Chemical Compound Fixed isotopic 
ratio ?
(Y/N)
… with which 
radionuclide? 
(eg
nnn
?? : 
239
Pu) 
Ratio
?
?
?
?
Unknown ?
Primary monitoring method(s) used to determine doses entered onto formal dose record  
(eg. PAS, lung monitoring, urine, faeces, etc.) 
Monitoring method(s) Radionu
clide
Chemical
Compound Routine monitoring Incident (special) monitoring 
Unknown 
Note.  If different techniques are used depending on magnitude of dose, please give this information 
in the table. 
A3.6 OTHER ACTINIDES 
A3.6.1 ROUTINE MONITORING 
IS THE ROUTINE MONITORING PROGRAMME FOR THIS ACTINIDE 
IDENTICAL TO THAT FOR ONE OF THE ACTINIDES SPECIFIED  
IN SECTIONS A3.1, A3.2, A3.3, A3.4, OR A3.5  ?
?
If YES, specify actinide :
 check that A3.x is completed fully, and then go to A3.6.2
If NO, we will contact you to request further information 
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A3.6 OTHER ACTINIDES 
A3.6.2 INCIDENT (SPECIAL) MONITORING 
IS THE INCIDENT MONITORING PROGRAMME FOR THIS ACTINIDE 
IDENTICAL TO THAT FOR ONE OF THE ACTINIDES SPECIFIED  
IN SECTIONS A3.1, A3.2, A3.3, A3.4, OR A3.5  ?
?
If YES, specify actinide : 
and check that A3.x.2 is completed fully. 
If NO, we will contact you to request further information 
SECTION 4  DOSE ASSESSMENT AND DOSE STATISTICS 
 Method 
  Manual calculation 
  Own software 
  LUDEP  
  CINDY  
  IMBA  
  Other (specify) 
Routine Monitoring: Intake assumptions 
 Single acute intake at mid-point of monitoring interval  
 Continuous chronic intake   
 “Best fit” to monitoring data   
 Other (specify below)    
 Is contribution from previous intakes subtracted ?  ?
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Individual internal dose statistics for the last year (  to )
 Range (mSv) Number in range 
 low doses possible, but not assessed 
 0.1 - 0.5 
 0.5 - 1 
 1    - 2 
 2    - 5 
 5    - 10 
 10  - 20 
 > 20 
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